Recursion Pharmaceuticals, Inc. (RXRX) Operating margin 2019–2025
Recursion Pharmaceuticals, Inc. (RXRX) operating margin by fiscal year — reported operating income divided by reported revenue.
-867.9%FY2025 · since FY2019: -2692.6% → -867.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -867.9% | -53.8 pp |
| FY2024 | -814.1% | -28.8 pp |
| FY2023 | -785.3% | -168.6 pp |
| FY2022 | -616.7% | +1179.0 pp |
| FY2021 | -1795.8% | +339.9 pp |
| FY2020 | -2135.7% | +556.9 pp |
| FY2019 | -2692.6% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More RXRX financial trends
RXRX RevenueRXRX Net incomeRXRX Net marginRXRX Gross profitRXRX Gross marginRXRX Operating incomeRXRX Operating cash flowRXRX Free cash flowRXRX Capital expendituresRXRX Return on equityRXRX Stock buybacksRXRX Dividends paidRXRX Total assetsRXRX Total liabilitiesRXRX Shareholders’ equityRXRX overview →